Capricor gains as new DMD study fuels therapy hopes
Capricor Therapeutics drew heavy retail attention on Monday after publishing a peer-reviewed study in Biomedicines validating the mechanism and potency of its Duchenne therapy Deramiocel. The late-stage HOPE-3 trial remains on track, with topline data due this quarter. Traders see renewed hope after Sarepta recent setback.